lifestyle.pspl.com

Author: BridgeBio Pharma, Inc.

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

May 2, 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

May 2, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

April 29, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

April 28, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

February 24, 2026
BridgeBio to Participate in March Investor Conferences

February 23, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 17, 2026
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

February 17, 2026
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

February 13, 2026